Market Place
Sourcing Support
MHRA Approves High-Dose SPINRAZA For Spinal Muscular Atrophy
14 Apr 2026 //
PHARMIWEB
Biogen Bets on $5.6 Billion buyout of Apellis
31 Mar 2026 //
GLOBENEWSWIRE
FDA Approves New High Dose Regimen of SPINRAZA for SMA
30 Mar 2026 //
GLOBENEWSWIRE
Biogen Presents New SMA Data at MDA, SMA Europe Conferences
05 Mar 2026 //
GLOBENEWSWIRE
Biogen Bets HD Spinraza Can Outmuscle Roche`s Oral Rival
06 Feb 2026 //
FIERCE PHARMA
Biogen`s High-Dose Spinraza Gets EU Nod for SMA
12 Jan 2026 //
GLOBENEWSWIRE
Canada Approves Biogen`s ZURZUVAE for Postpartum Depression
09 Dec 2025 //
PHARMIWEB
Stoke, Biogen Unveil Zorevunersen Data Syndrome for Dravet at AES
05 Dec 2025 //
PHARMIWEB
Stoke, Biogen Publish 2-Year Dravet Data
18 Nov 2025 //
BUSINESSWIRE
Nusinersen High Dose Regimen Gets Positive CHMP Opinion
17 Nov 2025 //
GLOBENEWSWIRE
Biogen, Stoke Present Zorevunersen Data In Dravet Syndrome
02 Sep 2025 //
PHARMAWEB
First Patient Dosed in Ph 3 Biogen, Stoke Dravet Study
11 Aug 2025 //
GLOBENEWSWIRE
Biogen, Stoke Reveal Zorevunersen Data for Dravet Syndrome
10 Jul 2025 //
GLOBENEWSWIRE
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
19 Feb 2025 //
BIOSPACE
n-Lorem Hosts Nano-Rare Colloquium With 750+ Attendees
12 Dec 2024 //
BUSINESSWIRE
Biogen in up to $1.8 bln deal as rare diseases take center stage
23 May 2024 //
REUTERS
Biogen 1Q Results
22 May 2024 //
CONTRACT PHARMA
Biogen`s top dealmaker is keen on rare disease meds
05 Mar 2024 //
FIERCE BIOTECH
Biogen`s rare genetic disorder drug gets approval in EU
13 Feb 2024 //
FIERCE PHARMA
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
29 Jul 2023 //
HEALTH ET
To be cost-effective, Biogen should slash Spinraza price
04 Apr 2019 //
ENDPTS
Orphan drugs from Biogen and Amicus win UK Prix Galien
17 Nov 2018 //
PM LIVE
An expensive new medication is finally available for her rare disease
10 Nov 2018 //
MARKET WATCH
Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
05 Nov 2018 //
ENDPTS
Biogen receives FDA orphan drug designation for treatment of SMA
18 Jul 2018 //
FDA
With tech from Spinraza’s maker, French startup Dynacure gets $55M
06 Jul 2018 //
ENDPTS
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ
23 Jan 2018 //
PMLIVE
3 Biotechs With Bulging Pipelines Could Also Become Attractive Takeover Targets
30 Jun 2017 //
BIOSPACE
Biogen rare infant disease drug Spinraza approved in E.U.
02 Jun 2017 //
BIZ JOURNALS
CHMP backs two rare disease therapies at April meeting
24 Apr 2017 //
PMLIVE
The world`s most pricey drugs, from a $1.2M gene therapy to a $450K lymphoma med
19 Apr 2017 //
FIERCE PHARMA
Biogen, Roche ink deals with Bristol for rare disease drugs
14 Apr 2017 //
BIOPHARMADIVE
The Cost of Drugs for Rare Diseases Is Threatening the U.S. Health Care System
10 Apr 2017 //
HARVARD BUSINESS REVIEW
Sky-High Drug Prices For Rare Diseases Show Why Orphan Drug Act Needs Reform
18 Mar 2017 //
HUFFINGTON POST
At rare disease panel, ex-FDA new drug head preaches evidence over empathy
03 Mar 2017 //
BIZ JOURNALS
